Hitgen Inc. Class A 688222
SSE · China · Health Technology
CNY 44.69+1.01 (+2.31%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, on dosing the first participant in QUELL-CV, a Phase 2 proof-of-concept clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor.
Mission BioCapital (MBC), in partnership with sponsors AbbVie, Ono Venture Investment (OVI), Toronto Innovation Acceleration Partners (TIAP), Connecticut Innovations, Alloy Therapeutics, HitGen, CCRM, Goodwin, Norton Rose Fulbright, and van den Boom & Associates announced today that applications are open internationally for the 2026 Platinum Program. MBC's Platinum Program aims to advance high-potential life sciences start-up companies by providing pre-seed funding, global laboratory space, expe
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.